id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-0874-0092,FDA,FDA-2021-N-0874,Final Decision on the Proposal To Refuse To Approve a New Drug Application for ITCA 650,Notice,General Notice,2024-08-23T04:00:00Z,2024,8,2024-08-23T04:00:00Z,,2024-08-23T18:25:03Z,2024-18898,0,0,090000648666c365
FDA-2021-N-0874-0090,FDA,FDA-2021-N-0874,"September 21, 2023 Endocrinologic and Metabolic Drugs Advisory Committee Meeting Transcript",Other,Transcript(s),2024-07-31T04:00:00Z,2024,7,2024-07-31T04:00:00Z,,2024-07-31T20:10:49Z,,0,0,090000648661047d
FDA-2021-N-0874-0088,FDA,FDA-2021-N-0874,"September 21, 2023 Endocrinologic and Metabolic Drugs Advisory Committee Intarcia Briefing Document",Other,Brief,2024-07-31T04:00:00Z,2024,7,2024-07-31T04:00:00Z,,2024-07-31T20:10:40Z,,0,0,0900006486610463
FDA-2021-N-0874-0091,FDA,FDA-2021-N-0874,"September 21, 2023 Endocrinologic and Metabolic Drugs Advisory Committee Meeting Questions",Other,Request,2024-07-31T04:00:00Z,2024,7,2024-07-31T04:00:00Z,,2024-07-31T20:10:54Z,,0,0,0900006486610480
FDA-2021-N-0874-0086,FDA,FDA-2021-N-0874,"September 21, 2023 Endocrinologic and Metabolic Drugs Advisory Committee CDER PowerPoint Presentation",Other,Presentation,2024-07-31T04:00:00Z,2024,7,2024-07-31T04:00:00Z,,2024-07-31T20:10:30Z,,0,0,090000648661045d
FDA-2021-N-0874-0087,FDA,FDA-2021-N-0874,"September 21, 2023 Endocrinologic and Metabolic Drugs Advisory Committee FDA Briefing Document",Other,Brief,2024-07-31T04:00:00Z,2024,7,2024-07-31T04:00:00Z,,2024-07-31T20:10:35Z,,0,0,090000648661045f
FDA-2021-N-0874-0089,FDA,FDA-2021-N-0874,"September 21, 2023 Endocrinologic and Metabolic Drugs Advisory Committee Intarcia PowerPoint Presentation",Other,Presentation,2024-07-31T04:00:00Z,2024,7,2024-07-31T04:00:00Z,,2024-07-31T20:10:45Z,,0,0,090000648661047a